Weiss Ratings reissued their sell (e+) rating on shares of 111 (NASDAQ:YI - Free Report) in a research note published on Thursday,Weiss Ratings reports.
111 Price Performance
Shares of NASDAQ:YI traded up $0.13 during trading on Thursday, hitting $8.39. 2,422 shares of the company were exchanged, compared to its average volume of 23,430. 111 has a 52-week low of $4.15 and a 52-week high of $14.10. The stock has a 50 day moving average of $8.35 and a 200 day moving average of $7.40. The company has a market cap of $71.75 million, a PE ratio of -2.10 and a beta of 0.57.
111 (NASDAQ:YI - Get Free Report) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.04) earnings per share (EPS) for the quarter. The company had revenue of $527.14 million during the quarter.
Institutional Trading of 111
A number of hedge funds and other institutional investors have recently bought and sold shares of YI. FIL Ltd purchased a new position in shares of 111 during the 4th quarter valued at $450,000. JPMorgan Chase & Co. boosted its stake in 111 by 43,619.9% during the fourth quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company's stock valued at $191,000 after buying an additional 305,339 shares during the period. Finally, Napean Trading & Investment Co Singapore PTE Ltd purchased a new position in 111 during the fourth quarter worth about $245,000. Institutional investors own 21.32% of the company's stock.
About 111
(
Get Free Report)
111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.
Read More
Before you consider 111, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 111 wasn't on the list.
While 111 currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
